LD50=230mg/kg (orally in mice)
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
Patients with this genotype have increased risk of severe neutropenia or severe diarrhea with drug; fluorouracil.
Patients with this genotype have reduced metabolism of fluorouracil and increased risk of toxicity.
Patients with this genotype have increased risk of toxicity with fluorouracil
Patients with this genotype have reduced metabolism of fluorouracil and increased risk of toxicity.
Patients with this genotype have reduced metabolism of fluorouracil and increased risk of toxicity.
The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from fluorouracil therapy.
The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from fluorouracil therapy.
The presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from fluorouracil therapy.
The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.
The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.
The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.
The presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from fluorouracil therapy.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Fluorouracil. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Fluorouracil. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Fluorouracil. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Fluorouracil. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Fluorouracil. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Fluorouracil. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Fluorouracil. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fluorouracil. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Fluorouracil. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Fluorouracil. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Fluorouracil. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Fluorouracil. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Fluorouracil. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Fluorouracil. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fluorouracil. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Fluorouracil. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fluorouracil. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Fluorouracil. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fluorouracil. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fluorouracil. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Fluorouracil. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fluorouracil. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Fluorouracil. |
| Flunisolide | The risk or severity of adverse effects can be increased when Flunisolide is combined with Fluorouracil. |
| Bortezomib | The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluorouracil. |
| Cladribine | Fluorouracil may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Fluorouracil. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Fluorouracil. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Fluorouracil. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Fluorouracil. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Fluorouracil. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Fluorouracil. |
| Vindesine | The risk or severity of adverse effects can be increased when Vindesine is combined with Fluorouracil. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Fluorouracil. |
| Indomethacin | The risk or severity of adverse effects can be increased when Indomethacin is combined with Fluorouracil. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Fluorouracil. |
| Vinorelbine | The risk or severity of adverse effects can be increased when Vinorelbine is combined with Fluorouracil. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Fluorouracil. |
| Beclomethasone dipropionate | The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Fluorouracil. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Fluorouracil. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Fluorouracil. |
| Teniposide | The risk or severity of adverse effects can be increased when Teniposide is combined with Fluorouracil. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Fluorouracil. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Fluorouracil. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Fluorouracil. |
| Cisplatin | The risk or severity of adverse effects can be increased when Cisplatin is combined with Fluorouracil. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Fluorouracil. |
| Vincristine | The risk or severity of adverse effects can be increased when Vincristine is combined with Fluorouracil. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Propylthiouracil. |
| Pentostatin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pentostatin. |
| Carbamazepine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Carbamazepine. |
| Vinblastine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Vinblastine. |
| Fluocinolone acetonide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fluocinolone acetonide. |
| Linezolid | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Linezolid. |
| Triamcinolone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Triamcinolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Clofarabine. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Pemetrexed. |
| Fludrocortisone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fludrocortisone. |
| Daunorubicin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Daunorubicin. |
| Irinotecan | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Irinotecan. |
| Etoposide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Etoposide. |
| Sulfasalazine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Sulfasalazine. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dacarbazine. |
| Temozolomide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Temozolomide. |
| Penicillamine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Penicillamine. |
| Prednisolone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Prednisolone. |
| Sirolimus | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Sirolimus. |
| Mechlorethamine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mechlorethamine. |
| Azacitidine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Carboplatin. |
| Methylprednisolone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Methylprednisolone. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dactinomycin. |
| Cytarabine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cytarabine. |
| Azathioprine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Azathioprine. |
| Doxorubicin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Doxorubicin. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Hydroxyurea. |
| Busulfan | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Busulfan. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Melphalan. |
| Fludarabine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Fludarabine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Flucytosine. |
| Trilostane | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Trilostane. |
| Procarbazine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Procarbazine. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Arsenic trioxide. |
| Idarubicin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Idarubicin. |
| Estramustine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Estramustine. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Mitoxantrone. |
| Lomustine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Lomustine. |
| Budesonide | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Budesonide. |
| Docetaxel | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Docetaxel. |
| Dasatinib | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dasatinib. |
| Eculizumab | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Eculizumab. |
| Decitabine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Decitabine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Nelarabine. |
| Corticotropin | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Corticotropin. |
| Cortisone acetate | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Cortisone acetate. |
| Paramethasone | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Paramethasone. |